426 related articles for article (PubMed ID: 15788425)
1. Survival of endothelial cells in vitro on Paclitaxel-loaded coronary stents.
Prasad CK; Resmi KR; Krishnan LK; Vaishnav R
J Biomater Appl; 2005 Apr; 19(4):271-86. PubMed ID: 15788425
[TBL] [Abstract][Full Text] [Related]
2. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells.
Blindt R; Vogt F; Astafieva I; Fach C; Hristov M; Krott N; Seitz B; Kapurniotu A; Kwok C; Dewor M; Bosserhoff AK; Bernhagen J; Hanrath P; Hoffmann R; Weber C
J Am Coll Cardiol; 2006 May; 47(9):1786-95. PubMed ID: 16682302
[TBL] [Abstract][Full Text] [Related]
3. [Drug-eluting stents do they make the difference? ].
Presbitero P; Asioli M
Minerva Cardioangiol; 2002 Oct; 50(5):431-42. PubMed ID: 12384625
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting stents.
García-García HM; Vaina S; Tsuchida K; Serruys PW
Arch Cardiol Mex; 2006; 76(3):297-319. PubMed ID: 17091802
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.
Scheller B; Speck U; Abramjuk C; Bernhardt U; Böhm M; Nickenig G
Circulation; 2004 Aug; 110(7):810-4. PubMed ID: 15302790
[TBL] [Abstract][Full Text] [Related]
6. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus. Implications for local drug delivery.
Wessely R; Blaich B; Belaiba RS; Merl S; Görlach A; Kastrati A; Schömig A
Thromb Haemost; 2007 Jun; 97(6):1003-12. PubMed ID: 17549304
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells.
Clever YP; Cremers B; Krauss B; Böhm M; Speck U; Laufs U; Scheller B
EuroIntervention; 2011 May; 7 Suppl K():K32-42. PubMed ID: 22027725
[TBL] [Abstract][Full Text] [Related]
8. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model.
Salu KJ; Bosmans JM; Huang Y; Hendriks M; Verhoeven M; Levels A; Cooper S; De Scheerder IK; Vrints CJ; Bult H
Cardiovasc Res; 2006 Feb; 69(2):536-44. PubMed ID: 16386237
[TBL] [Abstract][Full Text] [Related]
9. In situ endothelialization of intravascular stents coated with an anti-CD34 antibody functionalized heparin-collagen multilayer.
Lin Q; Ding X; Qiu F; Song X; Fu G; Ji J
Biomaterials; 2010 May; 31(14):4017-25. PubMed ID: 20149438
[TBL] [Abstract][Full Text] [Related]
10. Drug-eluting stents.
Chieffo A; Colombo A
Minerva Cardioangiol; 2002 Oct; 50(5):419-29. PubMed ID: 12384624
[TBL] [Abstract][Full Text] [Related]
11. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo.
Hacker TA; Griffin MO; Guttormsen B; Stoker S; Wolff MR
J Invasive Cardiol; 2007 Jun; 19(6):269-74. PubMed ID: 17541129
[TBL] [Abstract][Full Text] [Related]
12. The paclitaxel-eluting stent in percutaneous coronary intervention: part I: background and clinical comparison to bare metal stents.
Gruchalla KJ; Nawarskas JJ
Cardiol Rev; 2006; 14(2):88-98. PubMed ID: 16493246
[TBL] [Abstract][Full Text] [Related]
13. Arsenic trioxide eluting stent reduces neointima formation in a rabbit iliac artery injury model.
Yang W; Ge J; Liu H; Zhao K; Liu X; Qu X; Li W; Huang Y; Sun A; Zou Y
Cardiovasc Res; 2006 Dec; 72(3):483-93. PubMed ID: 17020754
[TBL] [Abstract][Full Text] [Related]
14. Polymer stent coating for prevention of neointimal hyperplasia.
Billinger M; Buddeberg F; Hubbell JA; Elbert DL; Schaffner T; Mettler D; Windecker S; Meier B; Hess OM
J Invasive Cardiol; 2006 Sep; 18(9):423-6; discussion 427. PubMed ID: 16954581
[TBL] [Abstract][Full Text] [Related]
15. Are impaired endothelial progenitor cells involved in the processes of late in-stent thrombosis and re-endothelialization of drug-eluting stents?
Zhao FH; Chen YD; Jin ZN; Lu SZ
Med Hypotheses; 2008; 70(3):512-4. PubMed ID: 17764856
[TBL] [Abstract][Full Text] [Related]
16. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.
Jaschke B; Michaelis C; Milz S; Vogeser M; Mund T; Hengst L; Kastrati A; Schömig A; Wessely R
Cardiovasc Res; 2005 Dec; 68(3):483-92. PubMed ID: 16111664
[TBL] [Abstract][Full Text] [Related]
17. Vascular delivery of c-myc antisense from cationically modified phosphorylcholine coated stents.
Chan KH; Armstrong J; Withers S; Malik N; Cumberland DC; Gunn J; Holt CM
Biomaterials; 2007 Feb; 28(6):1218-24. PubMed ID: 17126396
[TBL] [Abstract][Full Text] [Related]
18. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model.
Bhargava B; Reddy NK; Karthikeyan G; Raju R; Mishra S; Singh S; Waksman R; Virmani R; Somaraju B
Catheter Cardiovasc Interv; 2006 May; 67(5):698-702. PubMed ID: 16575925
[TBL] [Abstract][Full Text] [Related]
19. Novel polymeric coatings with the potential to control in-stent restenosis--an in vitro study.
Nickson CM; Doherty PJ; Williams RL
J Biomater Appl; 2010 Jan; 24(5):437-52. PubMed ID: 19033327
[TBL] [Abstract][Full Text] [Related]
20. Local paclitaxel delivery as a treatment of persistent, recurrent in-stent restenosis -- safety assessment.
Buszman P; Zurakowski A; Gruszka A; Szkróbka I; Peszek-Przybyła E; Radwan K; Milewski K; Barteczko Z; Tendera M
Kardiol Pol; 2006 Mar; 64(3):268-72; discussion 273-4. PubMed ID: 16583327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
